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Abstract
Febrile infection-related epilepsy syndrome (FIRES) is a devastating epilepsy
characterized by new-onset refractory status epilepticus with a prior febrile
infection. We performed exome sequencing in 50 individuals with FIRES,
including 27 patient–parent trios and 23 single probands, none of whom had
pathogenic variants in established genes for epilepsies or neurodevelopmental
disorders. We also performed HLA sequencing in 29 individuals with FIRES
and 529 controls, which failed to identify prominent HLA alleles. The genetic
architecture of FIRES is substantially different from other developmental and
epileptic encephalopathies, and the underlying etiology remains elusive, requir-
ing novel approaches to identify the underlying causative factors.
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Introduction
Febrile infection-related epilepsy syndrome (FIRES) is a
severe epileptic encephalopathy with new-onset super-
refractory status epilepticus that presents with a febrile
illness prior to seizure onset.1 Status epilepticus in indi-
viduals with FIRES is highly refractory, and, even
though a cytokine-mediated mechanism has been pro-
posed, the pathophysiology remains entirely unknown.2,3
FIRES shares many clinical features with developmental
and epileptic encephalopathies (DEE). Over the last two
decades, genetic studies have identified the underlying
cause of many previously poorly understood epilepsy
syndromes, including disease-causing SCN1A variants in
up to 90% of individuals with Dravet Syndrome4 and
disease-causing KCNT1 variants in a significant fraction
of individuals with epilepsy with migrating focal sei-
zures.5 Genetic testing has become a common diagnostic
modality and is routinely performed in children and
adults with DEE. The diagnostic yield is considered 15–
20%6,7 and reaches up to 50% in individuals with
neonatal epileptic encephalopathies,8 largely due to de
novo variants in genes encoding ion channels or synap-
tic proteins.
Ever since its initial description in 2010,1 the cause of
Febrile Infection-Related Epilepsy Syndrome (FIRES) has
been a matter of debate. Given the absence of otherwise
explanatory factors, two avenues of research have been
pursued to better understand the underlying disease
mechanism, including (1) the identification and delin-
eation of a potentially dysregulated immune response and
(2) genetic studies in parallel to genetic investigations in
other nonlesional epilepsies. While studies into the disease
mechanism have recently focused on a dysregulation of
the IL1 response9 with reports suggesting a promising
therapeutic effect of anakinra,10–13 the primary cause lead-
ing to this response is unknown.
Given the suspicion of an underlying genetic cause,
multiple studies over the last decade have assessed the
role of genetic factors in FIRES (detailed in Supplemen-
tary Information). However, excluding individuals subse-
quently included in our study, we only identified less
than 30 individuals with FIRES reported to have under-
gone sequencing for candidate genes, gene panel analysis,
or whole exome sequencing in these studies. A subset of
studies reported alleged genetic findings in FIRES. By cur-
rent diagnostic criteria, however, none of the findings
would be considered explanatory.
FIRES is extremely rare with less than 50 new cases in
the United States every year. Accordingly, assembling
patient cohorts is challenging. We therefore established an
international study to perform exome sequencing in indi-
viduals with FIRES. We reasoned that, in parallel to DEE,
autism, and other neurodevelopmental disorders, the
genetic basis of FIRES can be identified through a mod-
ern next-generation sequencing approach.
Patients and Methods
Subjects
We included a cohort of 50 individuals with FIRES from
centers in Kiel, Germany (n = 30), Paris, France (n = 9),
Israel (n = 7), Italy (n = 2), and the US (n = 2) for the
current study. The diagnosis of FIRES was confirmed by
two senior physicians (A.v.B., R.N.) based on consensus
criteria,14 and standardized phenotyping was obtained for
all individuals. The study was approved by the Institu-
tional Review Board of the University of Kiel, Germany,
Hôpital Necker-Enfants Malades, Paris, France, and Chil-
dren’s Hospital of Philadelphia.
Exome sequencing and HLA sequencing
Exome sequencing was performed for patient–parent trios
and singletons at four sites. Of these, 18 individuals were
sequenced at Broad institute with Nextera Rapid Capture
Exome kit through the Epi25 Project, 13 individuals at
Cologne Center for Genomics with Agilent Technologies
SureSelect V6 R2 kit, 11 individuals at Institut Imagine,
Paris with Agilent Technologies 50 V5 kit, and 6 individ-
uals with Truseq Exome Enrichment kit at the Institute of
Clinical Molecular Biology (ICMB), Kiel. Molecular HLA
typing was performed at ICMB using a targeted NGS
method as previously reported.15
Bioinformatic analysis for exome and HLA
sequencing
Exome data were analyzed through a bioinformatic
pipeline as previously described.16,17 Analysis for patho-
genic variants in genetic etiologies for human epilepsies
was performed according to criteria of the American
College of Medical Genetics and Genomics (ACMG).18
HLA imputation was performed using HLAscan,
including 29 cases and 529 controls of European ances-
try. Using PyHLA, significant HLA associations were
tested under an additive allelic model,19 correcting for
multiple testing using the Benjamini-Hochberg FDR
method.
Selection of FIRES candidate genes
In trio whole-exome data, we selected (a) de novo, X-
linked, and bi-allelic variants absent in population data-
bases. For both trio and singleton exome data, we
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further identified (b) ClinVar pathogenic variants,20 (c)
nonpopulation variants in 101 epilepsy-related genes,
(d) Protein Truncating Variants (PTV) in genes resis-
tant to loss-of-function variation (pLI score > 0.95),21
and (e) deleterious missense variants (CADD
score > 20) within constrained coding regions
(CCR > 95th percentile).22 The selection strategy for
these candidate genes is further outlined in the Supple-
mentary Information.
Results
Spectrum of clinical features
Our cohort included 17 females and 33 males (clinical
features are shown in Table S1). In brief, three individuals
(F3, F44, and F51) had prior febrile seizures, but none of
the individuals had epilepsy diagnosed prior to the onset
of FIRES. Median age of onset of the acute phase was
6 years (range 2–15 years). EEGs performed in the acute
phase showed epileptiform activity in 41/50, mostly mul-
tifocal discharges arising bilaterally from the frontal and
temporal regions. Developmental outcome was docu-
mented in 49/50 individuals, including 11/49 with mild,
18/49 with moderate, and 13/49 with severe intellectual
disability. Seven individuals had resolution of FIRES with-
out intellectual deficits. 44/47 individuals with docu-
mented development prior to seizure onset did not have
developmental concerns, the remaining three individuals
had anxiety and obsessive-compulsive disorder (F11),
attention deficit hyperactivity disorder (ADHD, F14), and
language delay (F43).
Exome sequencing
Known genetic etiologies in human epilepsies
None of the 50 individuals had pathogenic or likely
pathogenic variants in known genetic etiologies for
human epilepsies. The 27 patient–parent trios were fur-
ther analyzed for de novo, X-linked, and bi-allelic variants
absent in population databases (Table 1). No gene was
found to be affected by a de novo variant or bi-allelic
variants in two or more individuals. The only known
variant in a gene related to human epilepsies was a previ-
ously reported de novo c.G1117A (p.E373K) variant in
DNM1 in F26.23 However, as this variant in DNM1
occurred outside the typical mutation cluster and the pre-
sentation was incompatible with the typical phenotype, it
remained of uncertain significance. We next analyzed a
virtual panel of 101 curated epilepsy-related genes that
are typically analyzed in a diagnostic context (Table S2).
This analysis identified a total of seven variants absent in
population databases, including two variants in KCNQ3
(F38 and F28) and one variant in SCN2A (F29). The
KCNQ3 variant in F38 was paternally inherited and par-
ental testing was not available for F28. Both these KCNQ3
variants occurred in the C-terminal end, where popula-
tion variants in this gene are common and hence, a pro-
found effect on protein function is unlikely. The variant
c.A2851G (p.M951V) in SCN2A occurred close to the
selectivity filter, paralogous to SCN1A variants observed
in Dravet Syndrome.24 However, the variant in F29 was
inherited from an unaffected father and is not considered
explanatory for the individual’s epilepsy. All other non-
population variants in epilepsy genes occurred in genes
incompatible with the FIRES phenotype. The analysis of
ClinVar pathogenic variants identified a reported patho-
genic variant in FOXP2 (p.Q175delinsQQQQQ) in F47, a
known genetic etiology for speech disorders. As this vari-
ant was inherited from an unaffected father, we consider
it noncontributory to the FIRES phenotype.
Candidate variants and Copy Number Variation
(CNV) analysis
We identified de novo variants absent in population data-
bases in NPY2R, MYO1D, UNC50, SPICE1, NAV1, and
LRIF1. None of these genetic etiologies are established in
neurodevelopmental disorders or epilepsy, but occur in
brain-expressed genes intolerant to mutation, including
genes implicated in brain development (NPY2R, UNC50,
NAV1, Supplementary Information). We further assessed
potential candidate variants by identifying protein-trun-
cating variants in genes resistant to loss-of-function varia-
tion and missense variants in genomic regions devoid of
variation. We identified a total of seven protein truncat-
ing variants and 10 missense variants (Table 2). None of
the implicated genes are established causes for neurologi-
cal disease. Analysis of copy number variations from
exome sequences did not identify pathogenic deletions or
duplications (Supplementary Information).
HLA sequencing
We performed HLA sequencing in 29 individuals and
compared allelic associations with 529 population con-
trols. We did not identify a prominent HLA allele but
found tentative associations with HLA-C*07:01 [OR 8.7,
95% CI 3.55–21.30], HLA-A*02:05 [OR 12.99, 95% CI
3.56–47.39], and HLA*A: 03:01 [OR 0.1, 95% CI 0.01–
0.77]. Given the lack of a consistent HLA signature, we
consider these results inconclusive. None of the identified
HLA associations have previously been reported in other
disorders.
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Discussion
In our study, we aimed to identify the genetic basis of
FIRES using whole exome sequencing, reasoning that the
clinical features are related to developmental and epileptic
encephalopathies (DEE) where genetic causes are rou-
tinely identified. None of the individuals with FIRES had
explanatory variants in known genetic etiologies for
epilepsies or neurodevelopmental disorders. Even though
we identified several variants of uncertain significance in
known epilepsy-related genes and potential candidate
genes, none of the identified variants were considered dis-
ease-causing.
In our study, we do not observe the same rate of
pathogenic variants in established epilepsy genes that we
would expect in an equally-sized cohort of individuals
with DEE, such as Infantile Spasms or Lennox-Gastaut
Syndrome where the diagnostic rate is 15% or higher.
Assuming a comparable diagnostic rate for FIRES, we
would have expected at least three individuals with patho-
genic variants, allowing for the conclusion that the rate of
pathogenic or likely pathogenic variants in known epi-
lepsy genes in FIRES is low (95% CI 0–0.09 for variant
frequency in 0/50 individuals; P = 0.006 for null probabil-
ity of 0.15, see Supplementary Information). Status
epilepticus in FIRES is preceded by a mild febrile ill-
ness,14,25 suggesting a possible immune or inflammatory
mechanism. None of the candidate genes identified in our
study are implicated in human immunological disorders,
and HLA sequencing failed to identify a strong disease
Table 1. Candidate variants in FIRES.
ID Test Inheritance Gene Variant (c./p.) Protein name Transcripts
Variants with monogenic inheritance
F17 Trio de novo NPY2R c.A52G;p.K18E Neuropeptide y receptor y2 NM_000910.3
F23 Trio de novo MYO1D c.A1348G;p.K450E Myosin ID NM_001303279.1
F23 Trio de novo UNC50 c.582dupA;p.G194fs Unc-50 Inner nuclear membrane RNA
binding protein
NM_001330353.1
F23 Trio de novo SPICE1 c.G1540C;p.D514H Spindle- and centriole-associated protein
1
NM_001331078.1
F32 Trio de novo NAV1 c.G982A;p.G328S Neuron navigator 1 NM_020443.4
F7 Trio de novo LRIF1 c.C1585T;p.Q529X Ligand-dependent nuclear receptor-
interacting factor 1
NM_018372.3
F8 Trio Compound UNC79 c.G4087T;p.V1363L c.C4654A;
p.L1552I
Unc79 homolog, NALCN channel
complex subunit
NM_001346218.1
F29 Trio de novo KDM2B c.G3172A;p.V1058I Lysine-specific demethylase 2b NM_001005366.1
F32 Trio Compound KIAA0586 c.137delG;p.R46fs c.1793_1794del;
p.E598fs
KIAA0586 protein NM_001244191.1
F26 Single de novo1 DNM1 c.G1117A;p.E373K Dynamin 1 NM_004408.2
ClinVar pathogenic variants for neurological disorders
F27 Single Unknown SPG7 c.C1369T;p.R457X Paraplegin (Hereditary spastic paraplegia) NM_003119.3
F47 Trio Paternal FOXP2 c.525_526insCAGCAG CAACAA;
p.Q175delinsQQQQQ
Forkhead box protein p2 (Speech-
language disorder-1)
NM_148900.3
F17 Trio Maternal POLG c.G1399A;p.A467T DNA Polymerase Gamma, Catalytic
Subunit (Leigh Syndrome)
NM_001126131.1
F30 Trio Paternal CAPN3 c.549delA;p.P183fs Calpain 3 (Limb-girdle muscular
dystrophy)
NM_000070.2
Variants in genetic etiologies for epilepsy absent in gnomAD database
F35 Single Unknown GNAO1 c.A425C;p.N142T G Protein Subunit Alpha O1 NM_020988.2
F38 Single Homozygous LGI1 c.A615T;p.E205D Leucine-rich gene, glioma-inactivated, 1 NM_001308275.1
F38 Single Paternal KCNQ3 c.G1898A;p.G633E Potassium Voltage-Gated Channel
Subfamily Q Member 3
NM_004519.3
F38 Single Unknown ARX c.G503A;p.S168N Aristaless-related homeobox NM_139058.2
F27 Single Unknown ALG13 c.C905T;p.A302V UDP-N-Acetylglucosaminyl-transferase NM_001257230.1
F28 Single Unknown KCNQ3 c.G1854A;p.M618I Potassium Voltage-Gated Channel
Subfamily Q Member 3
NM_004519.3
F29 Trio Paternal SCN2A c.A2851G;p.M951V Sodium channel, voltage-gated, type ii,
alpha subunit
NM_001040143.1
1Previously published as de novo23.
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association. Tentative associations with HLA-C*07:01,
HLA-A*02:05, and HLA-A*03:01 were nonexplanatory.
We cannot exclude that inherited variants, including the
rare variants identified in our analysis, may contribute to
the risk of FIRES. However, given the low frequency of
FIRES and the small sample size, we are currently unable
to make a definite statement about the role of both rare
and common genetic variants in the etiology of FIRES.
Our study highlights that known genetic causes for epi-
lepsy are not common in FIRES, which may be important
in a diagnostic setting. Even though individuals with FIRES
will continue to undergo a genetic work-up, our data does
not provide a rationale for prioritizing genetic studies over
other diagnostic modalities. Likewise, our data advocates
against withholding specific anti-seizure medications based
on genetic considerations, including a reluctance to use
sodium channel blockers or valproic acid due to concerns
for an underlying sodium channelopathy or POLG-related
disorder. Examining non-genetic contributors or genetic
mechanisms not covered by exome sequencing will be criti-
cal for future research, including the analysis of repeat
expansions or non-coding regions that are increasingly rec-
ognized in neurological disorders.
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Table 2. Qualifying protein-truncating variants and missense variants in FIRES.
ID Test Inheritance Gene Variant (c./p.) Protein name Transcripts
Protein-truncating variants (PTV) with pLI > 0.95
F41 Single Unknown TBX1 c.1065_1066del;
p.P355fs
T-Box Transcription Factor 1 NM_080646.1
F33 Single Unknown GNAS c.G29A;p.W10X Guanine Nucleotide Binding Protein, Alpha Stimulating
Activity Polypeptide 1
NM_016592.3
F34 Single Unknown WWP2 c.G403T;
p.G135X
NEDD4-Like E3 Ubiquitin-Protein Ligase WWP2 NM_001270454.1
F51 Trio Paternal JAKMIP1 c.G2053T;
p.E685X
Janus Kinase and Microtubule Interacting Protein 1 NM_001099433.1
F1 Trio Maternal HSP90AB1 c.2172_2176del;
p.D724fs
Heat Shock Protein 90kDa Alpha (Cytosolic), Class B Member
1
NM_001271969.1
F30 Trio Maternal BRD1 c.1412delA;
p.D471fs
Bromodomain-containing protein 1 NM_001349940.1
F30 Trio Maternal ITGB8 c.C208T;p.Q70X Integrin, beta-8 NM_002214.2
Missense with phred-scaled CADD score > 20 and conserved coding region (CCR) percentile > 90
F35 Single Unknown ABCB6 c.A2175C;
p.K725N
Phosphatidylinositol glycan anchor biosynthesis class X protein NM_001349828.1
F35 Single Unknown MGAT4D c.T919A;p.F307I Mannosyl (Alpha-1,3-)-Glycoprotein Beta-1,4-N-
Acetylglucosaminyltransferase Family, Member D
NM_001277353.1
F38 Single Unknown DIP2C c.C3183G;
p.H1061Q
Disco-interacting protein 2 homolog C NM_014974.2
F22 Single Unknown NDUFAB1 c.A1C;p.M1L NADH-ubiquinone oxidoreductase 1 alpha/beta subcomplex,
1
NM_005003.2
F27 Single Unknown BCAS4 c.G619A;
p.A207T
Breast carcinoma amplified sequence 4 NM_017843.4
F46 Single Unknown RC3H2 c.G3164C;
p.R1055T
Ring finger and CCCH-type zinc finger domains-containing
protein 2
NM_001100588.1
F31 Trio Maternal CDKN2AIP c.C1708T;
p.P570S
Cyclin-dependent kinase inhibitor 2A-interacting protein NM_017632.3
F48 Trio Maternal HIST2H2AB c.C222G;p.N74K Histone gene cluster 2, H2A histone family, Member B NM_175065.2
F7 Trio Paternal GHRH c.A164C;p.Q55P Growth hormone-releasing hormone NM_001184731.2
F42 Single Unknown SLC25A1 c.526 + 1G>A Solute Carrier Family 25 (Mitochondrial Carrier; Citrate
Transporter), Member 1
NM_005984.4
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